March 31, 2017

MiRNA-based PD-1 pathway blockade for Human cancer therapy: MiR-410 decreases the activity of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 31/March/2017, 6.18 am

Introduction:What they say:  A recent study from Cell Signalling Section, Division of Immunology, Department of Pathology, Tennis Court Road, University of Cambridge, Cambridge CB2 1QP, UK […]
March 30, 2017

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: Agaricus blazei Murill (AbM) inhibits the expression of PD-L1, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 30/March/2017, 11.08 pm

Introduction:What they say: A recent study from Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, […]
March 30, 2017

Natural product-derived therapy for Human cancers: γ-Bisabolene, one of the main components of Cardamom, cubeb, oregano, and lemon among others, increases the expression of mitochondrial protein LACTB, decreases levels of mitochondrial phosphatidylserine decarboxylase, alters mitochondrial lipid metabolism, and promotes differentiation of breast cancer cells via up-regulation of its target gene, 30/March/2017, 9.51 am

Introduction: What they say: A study from the Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts, USA, Department of Biology, Massachusetts Institute of Technology, […]
March 30, 2017

Molecular therapy for enhancing the efficacy of tyrosine-kinase inhibitor (TKI) therapy in BCR-ABL-induced Human leukemia: Sodium butyrate (NaB), a histone deacetylase inhibitor, decreases the expression of oncoproteins c-FOS, DUSP1 and BCR-ABL, inhibits TKI resistance, restores treatment responsiveness, increases therapeutic index of anticancer drugs, and cure CML and kinase-driven cancers via up-regulation of its target gene, 30/March/2017, 8.40 am

Introduction: What they say: A study from the Division of Experimental Hematology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; Division of Pathology, Cincinnati Children’s Hospital […]